Immuno-oncology

Big pharma companies have become more measured in their risk taking, with mergers and acquisitions gradually giving way to joint ventures and partnerships.

The dual-action cell therapy is designed to eliminate established tumors, train the immune system to eradicate a primary tumor, and prevent recurrence.

The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.

An anti-cancer vaccine that is now in clinical trials shows promise as a preventative agent. However, experts are unsure when it will be widely available.

The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

Following the positive phase 3 results, GSK anticipates regulatory submissions in the first half of 2023.

Despite a limited understanding about access to oral anticancer drugs, new research finds challenges in patient and clinician decision-making.

The presence of CD8+ cells may help predict outcomes for patients administered immune checkpoint inhibitors.

Future research should investigate which therapies with new mechanisms of action add incremental benefit to existing treatment regimens for non-small cell lung cancer.

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

Biomarker testing and management of immune-related adverse events are key roles for pharmacists.

The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.

DeepTCR system showed efficacy as a predictive clinical tool and provided information on the biological mechanisms that underlie how patients respond to immunotherapy.

Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

GDA-501, a novel, genetically modified, nicotinamide natural killer pre-clinical cell therapy.

Study shows combining brentuximab vedotin with the standard chemotherapy regimen reduced the risk of relapse in children with high-risk Hodgkin lymphoma by 10%.

In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.

CAR T cells may have the ability to be engineered and remain consistently functional, leading to more effective cancer treatment.

A researcher suggests that novel immune modulating cancer therapies like cancer vaccines can be more effective and safer alternative to previous cancer immunotherapies.

Jeremy Graff, chief scientific officer at IMV, discusses why the development of viable cancer vaccines is a bit more slow-going in comparison to the fast-paced development of COVID-19 vaccines during the pandemic.

A researcher suggests that understanding specific cell function in the tumor microenvironment can help create effective and individualized immunotherapy cancer treatments.

Researchers identified a new immunotherapeutic target that may be effectively treated with CAR T-cell therapy in patients with pretreated multiple myeloma.

Yvonne Chen, PhD, discusses some of the strategies that researchers are using to improve T-cell effectiveness and overcome immunosuppression in CAR T-cell therapy.

Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.

Relapses remain a challenge in treating patients with leukemia.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

New research in immunotherapy is exploring vaccines to treat cancer, whether preventative or reactive against current tumors.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.

Yvonne Chen, PhD, discusses her research to engineer more safe and effective next-generation CAR-T therapy for cancer immunotherapy.